Rocket Pharmaceuticals (RCKT) Total Liabilities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Total Liabilities across 13 years of filings, most recently posting $47.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $47.4 million, down 19.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.4 million (down 19.62% YoY), and the FY2025 annual result was $53.2 million, down 17.43% from the prior year.
• Total Liabilities came in at $47.4 million for Q1 2026 at Rocket Pharmaceuticals, down from $53.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.8 million in Q4 2023 to a low of $42.5 million in Q1 2022.
• The 5-year median for Total Liabilities is $57.9 million (2024), against an average of $57.3 million.
• Peak annual rise in Total Liabilities reached 46.87% in 2022, while the deepest fall reached 55.92% in 2022.
• Rocket Pharmaceuticals' Total Liabilities stood at $62.1 million in 2022, then increased by 18.75% to $73.8 million in 2023, then slipped by 12.61% to $64.5 million in 2024, then retreated by 17.43% to $53.2 million in 2025, then slipped by 11.01% to $47.4 million in 2026.
• The last three Total Liabilities figures came in at $47.4 million (Q1 2026), $53.2 million (Q4 2025), and $54.4 million (Q3 2025), per Business Quant data.